Showing results (151-160 of 242) with videos related to

Sort By:
Pageof 25
Journal of Neuro-Oncology|May 6, 2010
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastomaDavid A Reardon, James J Vredenburgh, Annick Desjardins, et al.
Plos One|March 26, 2013
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in miceLuis A Sanchez-Perez, Bryan D Choi, Gary E Archer, et al.
The Journal of Clinical Investigation|September 10, 2014
miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathwaysHui Wang, Tao Sun, Jing Hu, et al.
Cancer Research|February 12, 2005
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acidChunhui Di, Shaoxi Liao, David C Adamson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastomaJames J Vredenburgh, Annick Desjardins, David A Reardon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomaJames J Vredenburgh, Annick Desjardins, James E Herndon, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2013
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomideLuis Sanchez-Perez, Bryan D Choi, Elizabeth A Reap, et al.
Molecular Cancer Therapeutics|October 15, 2009
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiformeJohn H Sampson, Gary E Archer, Duane A Mitchell, et al.
Toxicology Reports|June 2, 2018
Application of mutagen sensitivity assay in a glioma case-control studySerap Erdal, Bridget J McCarthy, Natalia Gurule, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant gliomaJill A Maxwell, Stewart P Johnson, Roger E McLendon, et al.
Pageof 25